当前位置: 首页 >> 检索结果
241. Double oral esomeprazole after a 3-day intravenous esomeprazole infusion reduces recurrent peptic ulcer bleeding in high-risk patients: a randomised controlled study.
作者: Hsiu-Chi Cheng.;Chung-Tai Wu.;Wei-Lun Chang.;Wei-Chun Cheng.;Wei-Ying Chen.;Bor-Shyang Sheu.
来源: Gut. 2014年63卷12期1864-72页
Patients with high Rockall scores have increased risk of ulcer rebleeding after 3-day esomeprazole infusions.
242. Carbon dioxide insufflation improves the intubation depth and total enteroscopy rate in single-balloon enteroscopy: a randomised, controlled, double-blind trial.
作者: Xuan Li.;Yun-Jia Zhao.;Jun Dai.;Xiao-Bo Li.;Han-Bin Xue.;Yao Zhang.;Guang-Su Xiong.;Kazuo Ohtsuka.;Yun-Jie Gao.;Qiang Liu.;Yan Song.;Jing-Yuan Fang.;Zhi-Zheng Ge.
来源: Gut. 2014年63卷10期1560-5页
The total enteroscopy rate of single-balloon enteroscopy (SBE) using air insufflation is not satisfactory, and whether carbon dioxide (CO2) insufflation increases the total enteroscopy rate of SBE is unknown. This randomised controlled trial aimed to determine whether CO2 insufflation facilitates the intubation depth and total enteroscopy rate of SBE.
243. Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN.
作者: H Fontaine.;S Kahi.;C Chazallon.;M Bourgine.;A Varaut.;C Buffet.;O Godon.;J F Meritet.;Y Saïdi.;M L Michel.;D Scott-Algara.;J P Aboulker.;S Pol.; .
来源: Gut. 2015年64卷1期139-47页
The antiviral efficacy of nucleos(t)ide analogues whose main limitation is relapse after discontinuation requires long-term therapy. To overcome the risk of relapse and virological breakthrough during long-term therapy, we performed a phase I/II, open, prospective, multicentre trial using a HBV envelope-expressing DNA vaccine.
244. The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial.
作者: Hideki Ishikawa.;Michihiro Mutoh.;Sadao Suzuki.;Shinkan Tokudome.;Yoshihisa Saida.;Takashi Abe.;Shozo Okamura.;Masahiro Tajika.;Takashi Joh.;Shinji Tanaka.;Shin-Ei Kudo.;Takahisa Matsuda.;Masaki Iimuro.;Tomomi Yukawa.;Tetsuji Takayama.;Yasushi Sato.;Kyowon Lee.;Shinji Kitamura.;Motowo Mizuno.;Yasushi Sano.;Nobuhisa Gondo.;Kenji Sugimoto.;Masato Kusunoki.;Chiho Goto.;Nariaki Matsuura.;Toshiyuki Sakai.;Keiji Wakabayashi.
来源: Gut. 2014年63卷11期1755-9页
To evaluate the influence of low-dose, enteric-coated aspirin tablets (100 mg/day for 2 years) on colorectal tumour recurrence in Asian patients with single/multiple colorectal tumours excised by endoscopy.
245. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial.
作者: Freddy Cornillie.;Stephen B Hanauer.;Robert H Diamond.;Jianping Wang.;Kezhen L Tang.;Zhenhua Xu.;Paul Rutgeerts.;Séverine Vermeire.
来源: Gut. 2014年63卷11期1721-7页
Serum infliximab trough levels correlate with efficacy; dose escalation is often beneficial in patients with Crohn's disease who stop responding to infliximab treatment.
246. Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid.
作者: Andrew J Cockbain.;Milene Volpato.;Amanda D Race.;Alessandra Munarini.;Chiara Fazio.;Andrea Belluzzi.;Paul M Loadman.;Giles J Toogood.;Mark A Hull.
来源: Gut. 2014年63卷11期1760-8页
Oral administration of the omega-3 fatty acid eicosapentaenoic acid (EPA), as the free fatty acid (FFA), leads to EPA incorporation into, and reduced growth of, experimental colorectal cancer liver metastases (CRCLM).
247. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea.
作者: Klara Garsed.;Julia Chernova.;Margaret Hastings.;Ching Lam.;Luca Marciani.;Gulzar Singh.;Amanda Henry.;Ian Hall.;Peter Whorwell.;Robin Spiller.
来源: Gut. 2014年63卷10期1617-25页
Irritable bowel syndrome with diarrhoea (IBS-D) is particularly debilitating due to urgency and episodic incontinence. Some 5-hydroxytryptamine 3 (5-HT3) receptor antagonists (5-HT3RAs) have proven effective but have serious side effects. Ondansetron, also a 5-HT3RA, has been widely used as an antiemetic with an excellent safety record for over two decades. Our aim was to assess its effectiveness in IBS-D.
248. Multinational, double-blind, randomised, placebo-controlled, prospective study of esomeprazole in the prevention of recurrent peptic ulcer in low-dose acetylsalicylic acid users: the LAVENDER study.
作者: Kentaro Sugano.;Myung-Gyu Choi.;Jaw-Town Lin.;Shinya Goto.;Yasushi Okada.;Yoshikazu Kinoshita.;Hiroto Miwa.;Chern-En Chiang.;Tsutomu Chiba.;Masatsugu Hori.;Yasushi Fukushima.;Hyun-Soo Kim.;Chi-Yang Chang.;Masataka Date.; .
来源: Gut. 2014年63卷7期1061-8页
To evaluate if esomeprazole prevents recurrent peptic ulcer in adult patients with a history of peptic ulcer receiving low-dose acetylsalicylic acid (ASA, aspirin) for cardiovascular protection in East Asia.
249. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial.
作者: Kevin S H Liu.;Ivan F N Hung.;W K Walter Seto.;Teresa Tong.;Axel S J Hsu.;Frank Y F Lam.;David Y K But.;S Y Wong.;Wai K Leung.
来源: Gut. 2014年63卷9期1410-5页
Treatments with sequential therapy (SEQ) or bismuth quadruple (QUAD) therapy have been proposed as empirical firstline regimens for Helicobacter pylori. We compared the efficacy and tolerability of 10 day SEQ with 10 day modified QUAD as both firstline and secondline treatments for H pylori in a randomised crossover study.
250. Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C.
作者: M Colombo.;I Fernández.;D Abdurakhmanov.;P A Ferreira.;S I Strasser.;P Urbanek.;C Moreno.;A Streinu-Cercel.;A Verheyen.;W Iraqi.;R DeMasi.;A Hill.;J M Läuffer.;I Lonjon-Domanec.;H Wedemeyer.
来源: Gut. 2014年63卷7期1150-8页
Severe adverse events (AEs) compromise the outcome of direct antiviral agent-based treatment in patients with advanced liver fibrosis due to HCV infection. HEP3002 is an ongoing multinational programme to evaluate safety and efficacy of telaprevir (TVR) plus pegylated-interferon-α (PEG-IFNα) and ribavirin (RBV) in patients with advanced liver fibrosis caused by HCV genotype 1 (HCV-1).
251. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
作者: Ad A van Bodegraven.;Nathalie Bravenboer.;Birgit I Witte.;Gerard Dijkstra.;C Janneke van der Woude.;Pieter C M Stokkers.;Maurice G Russel.;Bas Oldenburg.;Marieke Pierik.;Jan C Roos.;Ruud A van Hogezand.;Vincent K Dik.;Angela E Oostlander.;J Coen Netelenbos.;Lex van de Langerijt.;Daniel W Hommes.;Paul Lips.; .
来源: Gut. 2014年63卷9期1424-30页
Osteoporosis and fractures are frequently encountered in patients with Crohn's disease. In order to prevent fractures, treatment with bone protecting drugs appears warranted early in the course of bone disease when bone loss is not yet prominent. We therefore aimed to demonstrate a beneficial effect on bone density of the bisphosphonate risedronate in osteopenic Crohn's disease patients.
252. Interaction between preprandial and postprandial rectal sensory and motor abnormalities in IBS.
Rectal sensory and motor interactions in patients with IBS have not been studied in detail. The aim of this study was to evaluate fasting and postprandial rectal sensorimotor characteristics and their interactions in IBS compared with healthy controls.
253. Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes.
作者: Pinelopi Manousou.;Evangelos Cholongitas.;Dimitrios Samonakis.;Emmanuel Tsochatzis.;Alice Corbani.;A P Dhillon.;Janice Davidson.;Manuel Rodríguez-Perálvarez.;D Patch.;J O'Beirne.;D Thorburn.;Tuvinh Luong.;K Rolles.;Brian Davidson.;P A McCormick.;Peter Hayes.;Andrew K Burroughs.
来源: Gut. 2014年63卷6期1005-13页
Early results of a randomised trial showed reduced fibrosis due to recurrent HCV hepatitis with tacrolimus triple therapy (TT) versus monotherapy (MT) following transplantation for HCV cirrhosis. We evaluated the clinical outcomes after a median 8 years of follow-up, including differences in fibrosis assessed by collagen proportionate area (CPA).
254. Waist belt and central obesity cause partial hiatus hernia and short-segment acid reflux in asymptomatic volunteers.
作者: Yeong Yeh Lee.;Angela A Wirz.;James G H Whiting.;Elaine V Robertson.;Donald Smith.;Alexander Weir.;Andrew W Kelman.;Mohammad H Derakhshan.;Kenneth E L McColl.
来源: Gut. 2014年63卷7期1053-60页
There is a high incidence of inflammation and metaplasia at the gastro-oesophageal junction (GOJ) in asymptomatic volunteers. Additionally, the majority of patients with GOJ adenocarcinomas have no history of reflux symptoms. We report the effects of waist belt and increased waist circumference (WC) on the physiology of the GOJ in asymptomatic volunteers.
255. A novel urine peptide biomarker-based algorithm for the prognosis of necrotising enterocolitis in human infants.
作者: Karl G Sylvester.;Xuefeng B Ling.;G Y Liu.;Zachary J Kastenberg.;Jun Ji.;Zhongkai Hu.;Sihua Peng.;Ken Lau.;Fizan Abdullah.;Mary L Brandt.;Richard A Ehrenkranz.;Mary Catherine Harris.;Timothy C Lee.;Joyce Simpson.;Corinna Bowers.;R Lawrence Moss.
来源: Gut. 2014年63卷8期1284-92页
Necrotising enterocolitis (NEC) is a major source of neonatal morbidity and mortality. The management of infants with NEC is currently complicated by our inability to accurately identify those at risk for progression of disease prior to the development of irreversible intestinal necrosis. We hypothesised that integrated analysis of clinical parameters in combination with urine peptide biomarkers would lead to improved prognostic accuracy in the NEC population.
256. Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B.
作者: Ching-Lung Lai.;Sang Hoon Ahn.;Kwan Sik Lee.;Soon Ho Um.;Mong Cho.;Seung Kew Yoon.;Jin-Woo Lee.;Neung Hwa Park.;Young-Oh Kweon.;Joo Hyun Sohn.;Jiyoon Lee.;Jeong-Ae Kim.;Kwang-Hyub Han.;Man-Fung Yuen.
来源: Gut. 2014年63卷6期996-1004页
Besifovir (LB80380) is an acyclic nucleotide phosphonate effective in hepatitis B virus (HBV) DNA suppression for both treatment-naive and lamivudine-resistant chronic hepatitis B (CHB) patients in preliminary studies.
257. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial.
作者: Laurent Peyrin-Biroulet.;Walter Reinisch.;Jean-Frederic Colombel.;Gerassimos J Mantzaris.;Asher Kornbluth.;Robert Diamond.;Paul Rutgeerts.;Linda K Tang.;Freddy J Cornillie.;William J Sandborn.
来源: Gut. 2014年63卷1期88-95页
The Crohn's Disease Activity Index (CDAI) has been criticised due to heavy weighting on subjective clinical symptoms. C-reactive protein (CRP) and endoscopic lesions are objective measures of inflammation. We investigated the relationships between clinical disease activity, CRP normalisation and mucosal healing in Crohn's disease (CD).
258. Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea: origin and effect of gut transit.
作者: David Tooth.;Klara Garsed.;Gulzar Singh.;Luca Marciani.;Ching Lam.;Imogen Fordham.;Annie Fields.;Rawinder Banwait.;Melanie Lingaya.;Robert Layfield.;Maggie Hastings.;Peter Whorwell.;Robin Spiller.
来源: Gut. 2014年63卷5期753-60页
Faecal serine proteases (FSPs) may play a role in irritable bowel syndrome with diarrhoea (IBS-D), but their origin is unclear. We aimed to structurally characterise them and define the impact of colonic cleansing and transit time.
259. Fatigue management in patients with IBD: a randomised controlled trial.
作者: Lauran Vogelaar.;Adriaan van't Spijker.;Reinier Timman.;Antonie J P van Tilburg.;DirkJan Bac.;Ton Vogelaar.;Ernst J Kuipers.;Jan J V van Busschbach.;Christien J van der Woude.
来源: Gut. 2014年63卷6期911-8页
To assess the effectiveness of solution-focused therapy (SFT) on fatigue and quality of life (QoL) in patients with fatigued inflammatory bowel disease (IBD).
260. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.
作者: Casper Steenholdt.;Jørn Brynskov.;Ole Østergaard Thomsen.;Lars Kristian Munck.;Jan Fallingborg.;Lisbet Ambrosius Christensen.;Gitte Pedersen.;Jens Kjeldsen.;Bent Ascanius Jacobsen.;Anne Sophie Oxholm.;Jakob Kjellberg.;Klaus Bendtzen.;Mark Andrew Ainsworth.
来源: Gut. 2014年63卷6期919-27页
Although the reasons for secondary loss of response to infliximab (IFX) maintenance therapy in Crohn's disease vary, dose intensification is usually recommended. This study investigated the cost-effectiveness of interventions defined by an algorithm designed to identify specific reasons for therapeutic failure.
|